Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein

Clinical Pharmacology and Therapeutics

Volumn 68, Issue 1, 2000, Pages 6-12

  Westphal, Kristin ^a   Weinbrenner, Anita ^a   Giessmann, Thomas ^a   Stuhr, Marko ^a   Franke, Gerd ^a   Zschiesche, Michael ^a   Oertel, Reinhard ^a,b   Terhaag, Bernd ^a,c   Kroemer, Heyo K ^a   Siegmund, Werner ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c Arzneimittelwerk Dresden GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CONTRACEPTIVE AGENT; DIGOXIN; GASTROINTESTINAL POLYPEPTIDE; GLYCOPROTEIN P; RIFAMPICIN; TALINOLOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DISPOSITION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG PROTEIN BINDING; FEMALE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CARDIOTONIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DIGOXIN; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; INTESTINAL ABSORPTION; MALE; P-GLYCOPROTEIN; PROPANOLAMINES; REFERENCE VALUES; TIME FACTORS;

EID: 0033865280     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.107579     Document Type: Article

References (46)

1. Cellular localization of the multidrug-resistance gene product p-glycoprotein in normal human tissues
2. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues
3. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier
4. The barrier function of CYP3A4 and P-glycoprotein in the small bowel
5. Structure and function of p-glycoprotein in normal liver and small intestine
6. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption
7. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A
8. Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells
9. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1 a P-glycoprotein
10. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833
11. Inhibition of P-glycoprotein-mediated drug transport
12. The interaction of digoxin and rifampin: Role of intestinal P-glycoprotein
13. Direct demonstration of small intestinal secretion and site-dependent absorption of the β-blocker talinolol in humans
14. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil
15. Talinolol-rifampicin interaction: Potential role of drug transporters [abstract]
16. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies
17. Elucidation of the structure of talinolol metabolites in man: Determination of talinolol and hydroxylated talinolol metabolites in urine and analysis of talinolol in serum
18. Current status of cardiac glycoside drug interactions
19. Metabolism of digoxin, digoxigenin, digitoxosides and digoxigenin in human hepatocytes and liver microsomes
20. Pharmacokinetics of digoxin and main metabolites/derivatives in healthy humans
21. Untersuchungen tiber die Wirkung von Talinolol auf die Aktivitat der mischfunktionellen Oxidasen der Rattenleber
22. Digoxin-cyclosporine interaction: Modulation of the multidrug transporter P-glycoprotein in the kidney
23. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney
24. Cylclosporin and quinidine inhibition of renal digoxin excretion: Evidence for luminal secretion of digoxin
25. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin
26. Inhibition of the intestinal digoxin absorption and exsorption by quinidine
27. Energy-dependent transport of digoxin across renal tubular cell monolayers (LLC-PK1)
28. The mechanism of the verapamil-digoxin interaction in renal tubular cells (LLC-PK1)
29. 1)
30. Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein
31. Interaction between quinidine and digoxin
32. Anstieg der Digoxinkonzentration im Serum unter Chinidinmedikation
33. Digoxin-quinidine interaction: Pharmacokinetic evaluation
34. Effect of quinidine on digoxin bioavailability
35. Quinidine reduces biliary clearance of digoxin in man
36. Interaction between digoxin and calcium antagonists and antiarrhythmic drugs
37. Digoxin-verapamil interaction
38. Amiodarone-digoxin interaction: Clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications
39. Pharmacokinetic evaluation of the digoxin-amiodarone interaction
40. Interaction between digoxin and propafenone
41. The effects of cardiac transplantation and cyclosporine therapy on digoxin pharmacokinetics
42. Itraconazole increases serum digoxin concentrations
43. Itraconazole decreases renal clearance of digoxin
44. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: Concentration- and dose-dependent absorption in vitro and in vivo
45. P-glycoprotein transporters and the gastrointestinal tract: Evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound